ANI Pharmaceuticals completes acquisition of Alimera Sciences
Click Here to Manage Email Alerts
ANI Pharmaceuticals finalized its acquisition of Alimera Sciences, according to a press release.
The acquisition is part of ANI’s bid to grow its rare disease business as well as bolster its position in ophthalmology, according to the release. Under the agreement, ANI bought Alimera’s outstanding shares for $5.50 per share and repaid approximately $72.5 million of Alimera’s debt.
ANI acquired Alimera’s Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) for diabetic macular edema treatment and Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) for uveitis treatment. According to the release, the acquisition will help expand the reach of ANI’s ophthalmology sales team to more than 3,600 physicians.
“With this acquisition, ANI now has three commercial rare disease assets, an expanded global footprint, and a robust rare disease team covering the specialties of ophthalmology, neurology, nephrology, rheumatology and pulmonology,” ANI president and CEO Nikhil Lalwani said in the release.
Read more about
Click Here to Manage Email Alerts